Article thumbnail
Location of Repository

Supplementary Material

By Ching-Yuan Kuo (5322680), Po-Nan Wang (5322668), Wen-Li Hwang (429270), Cheng-Hwai Tzeng (398474), Li-Yaun Bai (5322674), Jih-Luh Tang (399697), Ming-Chih Chang (5322659), Sheng-Fung Lin (165405), Tsai-Yun Chen (3142089), Yeu-Chin Chen (751063), Tran-Der Tan (5322665), Chih-Yi Hsieh (5322662), Chinjune Lin (5322683), Clinton Lai (5322671), Darko Miljkovic (5322677) and Cheng-Shyong Chang (75246)

Abstract

<p>Supplemental material, Supplementary_Figure-1_submission_TAH for Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study by Ching-Yuan Kuo, Po-Nan Wang, Wen-Li Hwang, Cheng-Hwai Tzeng, Li-Yaun Bai, Jih-Luh Tang, Ming-Chih Chang, Sheng-Fung Lin, Tsai-Yun Chen, Yeu-Chin Chen, Tran-Der Tan, Chih-Yi Hsieh, Chinjune Lin, Clinton Lai, Darko Miljkovic and Cheng-Shyong Chang in Therapeutic Advances in Hematology</p

Topics: Cardiology, Oncology and Carcinogenesis not elsewhere classified, Pharmacology and Pharmaceutical Sciences not elsewhere classified, chronic myeloid leukemia, clinical trial, imatinib-resistant, nilotinib
Year: 2018
OAI identifier: oai:figshare.com:article/6397328
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://figshare.com/articles/... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.